DongJia Peptide has announced the implementation of an enhanced quality control protocol covering all peptide batches. The new protocol includes expanded third-party testing for purity, endotoxin levels, residual solvents, and heavy metals. Each product is now assigned a unique batch number, allowing clients to access detailed production and testing records. Certificates of Analysis (COA) are available upon request, providing full transparency and traceability. "Quality is our top priority," said the company's quality assurance manager. "These enhanced protocols ensure that our clients receive consistently high-quality products they can trust for their research." The company also announced that all products will continue to be shipped with clear storage and handling instructions, along with secure, temperature-controlled packaging for sensitive shipments.

Industry analysts report continued strong growth in the global peptide therapeutics market, with projections suggesting the market could exceed $50 billion by 2030. The expansion is primarily driven by increasing demand for GLP-1 receptor agonists used in weight loss and metabolic health research. Research into peptide-based treatments for obesity, diabetes, and metabolic disorders has accelerated significantly over the past two years. Peptides such as Semaglutide and Tirzepatide have become focal points for research institutions and pharmaceutical developers worldwide. As a supplier of high-purity research peptides, DongJia Peptide is well-positioned to support this growing research demand. The company ensures all products meet international research standards through rigorous third-party testing.

DongJia Peptide has expanded its product portfolio with the addition of three premium beauty peptides: GHK-Cu (Copper Tripeptide-1), Matrixyl (Palmitoyl Tripeptide-1), and Argireline (Acetyl Hexapeptide-8). These products are widely used in anti-aging, wrinkle reduction, and skin repair research. All three products are available in research-grade quantities and bulk packaging, with ≥99% purity verified by third-party HPLC testing. Certificates of Analysis (COA) are available upon request. The company plans to continue expanding its product line throughout the year, with additional weight loss peptides and custom synthesis services expected to launch in the coming months.

DongJia Peptide has officially launched its global operations, marking the company's entry into the international research peptide market. The company is headquartered in the UK and will focus on supplying high-purity weight loss peptides and beauty peptides to research institutions and wholesale distributors worldwide. "We are committed to providing researchers and partners with reliable, high-quality products backed by transparent testing and professional service," said a company spokesperson. The company has established logistics partnerships across Europe, North America, and Asia to ensure efficient door-to-door delivery. With a dedicated customer support team, DongJia Peptide aims to respond to all inquiries within 24 hours.